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ABSTRACT
Breast cancer stem cells (BCSCs) are pan-resistant to different anticancer agents 
and responsible for cancer relapse. Disulfiram (DS), an antialcoholism drug, targets 
CSCs and reverses pan-chemoresistance. The anticancer application of DS is limited 
by its very short half-life in the bloodstream. This prompted us to develop a liposome-
encapsulated DS (Lipo-DS) and examine its anticancer effect and mechanisms in vitro 
and in vivo. 
The relationship between hypoxia and CSCs was examined by in vitro comparison 
of BC cells cultured in spheroid and hypoxic conditions. To determine the importance 
of NFκB activation in bridging hypoxia and CSC-related pan-resistance, the CSC 
characters and drug sensitivity in BC cell lines were observed in NFκB p65 transfected 
cell lines. The effect of Lipo-DS on the NFκB pathway, CSCs and chemosensitivity was 
investigated in vitro and in vivo.
The spheroid cultured BC cells manifested CSC characteristics and pan-resistance 
to anticancer drugs. This was related to the hypoxic condition in the spheres. Hypoxia 
induced activation of NFκB and chemoresistance. Transfection of BC cells with NFκB 
p65 also induced CSC characters and pan-resistance. Lipo-DS blocked NFκB activation 
and specifically targeted CSCs in vitro. Lipo-DS also targeted the CSC population in 
vivo and showed very strong anticancer efficacy. Mice tolerated the treatment very 
well and no significant in vivo nonspecific toxicity was observed.
Hypoxia induced NFκB activation is responsible for stemness and chemoresistance 
in BCSCs. Lipo-DS targets NFκB pathway and CSCs. Further study may translate DS 
into cancer therapeutics.
INTRODUCTION
Chemoresistance is the major hindrance for the 
success of advanced/metastatic BC (A/MBC) treatment. 
The relapsed A/MBC is commonly pan-resistant to a wide 
range of anticancer drugs, which cannot be explained by 
individual genetic and biochemical resistant pathway. BC 
is a highly heterogeneous disease containing a very small 
fraction (1%) of cancer stem cell (CSC) [1] population 
with stem cell characters e.g. self-renewal, development 
into the original tumors in immune deficient mice, 
differentiation into several linages of progenies. BCSCs 
can be detected by stem cell markers (ALDH+, CD24Low/
CD44High) and activation of embryonic related pathways 
(Sox2, Oct4, Nanog) [2]. BCSCs are relatively quiescent 
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and pan-chemoresistant [3, 4]. Conventional anticancer 
drugs fail to eradicate the BCSCs, which become the 
source of tumor recurrence. 
Emerging evidence suggests that CSCs reside in a 
hypoxic/necrotic tumorous area named the CSC niche [5]. 
A wide range of studies has demonstrated that hypoxia 
plays pivotal roles in maintenance of the stemness of 
CSCs. The hypoxia-induced CSC characteristics can 
be reversed into a differentiated phenotype in normoxic 
condition and vice versa. In vitro, the CSC and non-
CSC phenotypes are interconversible in spheroid and 
monolayer culture respectively [6, 7]. Therefore the 
environmental oxygen concentration plays determinant 
roles in maintaining stemness in CSCs [8]. Although 
most of the publications emphasize the importance of 
the hypoxia inducible factors (HIFs) in induction and 
maintenance of CSC phenotypes, the molecular links 
between hypoxia and CSCs are still not fully elucidated. 
More than 20 transcription factors including NFκB are 
induced by hypoxia [9]. Hypoxia induces NFκB activation 
in a wide range of cells [6]. NFκB plays important role 
in cell survival, proliferation, invasion, migration and 
chemoresistance [10, 11]. Human NFκB is composed 
of 5 subunits [p50/p105, p52/p100, p65 (RelA), RelB 
and c-Rel], which form homo- or heterodimer binding 
to DNA target sites (κB sites) to influence downstream 
gene expression. The most common dimer is a p50-RelA 
heterodimer. In most normal cells, NFκB is sequestered in 
the cytoplasm as an inactive complex through the direct 
binding to its natural inhibitor, the inhibitor of NFκB 
(IκB). Upon various stimuli, IκB will be phosphorylated, 
ubiquitinated and promptly degraded which releases NFκB 
from NFκB-IB complex. The liberated NFκB dimers are 
then translocated into the nucleus and trigger a series of 
molecular reactions. Hypoxic activation of NFκB pathway 
may be HIF1α-dependent. HIF1α may directly interact 
with NFκB proteins to promote its DNA binding activity 
[12-14]. In addition to HIF-mediated activation of NFκB, 
it is recently demonstrated that hypoxia can directly 
induce NFκB which in turn regulates HIF pathway. The 
promoter region of HIF1α contains κB site. The activation 
of NFκB induced by TNFα and p50/p65 transfection 
lead to increased levels of HIF1α mRNA and protein. 
Therefore NF-κB can regulate HIF1α signaling pathway 
to maintain the basal levels of HIF1α under normoxic 
condition and further induces it under hypoxia [15, 16]. 
NFκB also induces HIF2α activation via influence of 
the interaction between IKKγ and CBP/p300 [17, 18]. 
Recent studies indicate that NFκB plays a pivotal role in 
hypoxia-induced CSC phenotypes and is responsible for 
the chemoresistance in CSCs [19].
It is widely accepted that development of anti-
CSC drugs to target CSC determinant pathways will 
improve chemotherapeutic outcomes. Disulfiram (DS), 
a commercially available anti-alcoholism drug [20], 
shows anticancer activity in vitro and in vivo [21-24]. 
Our previous studies demonstrate that DS enhances 
5-fluorouracil, paclitaxel (PTX) and gemcitabine (dFdC) 
induced apoptosis in colon, breast and brain cancer cell 
lines [21, 25-27]. The randomized clinical trial indicates 
that in combination with chemotherapy, ditiocarb, the 
derivative of DS, significantly improves the 5-year overall 
survival of high risk BC patients [28]. The anticancer 
activity of DS is copper (Cu) dependent [22, 29]. Cu plays 
a crucial role in redox reactions and triggers the generation 
of reactive oxygen species (ROS) in human cells. DS/
Cu is a strong ROS inducer [30] and proteasome-NFκB 
pathway inhibitor [21, 22, 25]. DS specifically inhibits 
the activity of aldehyde dehydrogenase (ALDH), a 
functional marker of CSCs and ROS scavenger [31, 32]. 
Combination of DS with Cu may target cancer cells by 
simultaneous modulation of both ROS and NFκB. DS and 
its metabolites can also permanently inhibit Pgp activity 
[33].
Although the anticancer activity of DS has been 
reported for a long time, only very few successful cases 
have been reported in clinic [28, 34]. This discrepancy 
may be mainly introduced by the very short half-life of 
DS in the bloodstream. Nano-technology may be able 
to extend the half-life of DS and translate it into cancer 
indication. In this study, we investigated the effect of 
hypoxia on CSCs and elucidated the bridging role of 
NFκB in linking hypoxia and CSCs. We also examined 
the in vitro and in vivo anticancer efficacy of a newly 
developed liposome-encapsulated DS (Lipo-DS). Our data 
indicate that NFκB plays a key role in pan-resistance of 
hypoxia-induced CSCs. Lipo-DS can efficiently abolish 
CSCs and reverse chemoresistance.
RESULTS
Hypoxia is responsible for maintaining stemness 
and drug resistance in mammosphere (MSC) and 
suspension cells (SUS)
In this study, we examined if the traditional stem cell 
culture system is essential for maintaining the stemness in 
vitro. Two breast cancer cell lines were cultured in both 
classical serum-free spheroid stem cell culture system and 
serum-rich (10%) medium in parallel. After 7 days culture, 
BC cells formed typical mammospheres in both conditions. 
The serum-free medium cultured cells formed numerous 
relatively smaller spheres which loosely aggregated 
together. In contrast, the cells cultured in the serum-rich 
medium formed markedly larger and tighter spheres 
(Fig. 1A). Furthermore, we compared the expression 
of stem cell markers and CSC-related embryonic 
proteins in these cells. Both MSCs and SUS cells have 
significantly higher proportion of cells expressing stem 
cell markers (ALDH+ and CD24low/CD44high) and CSC-
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related embryonic proteins (Sox2, Nanog and Oct4). In 
comparison with the MSCs, most of these proteins are 
expressed at higher levels in the SUS cells (Fig. 1B). 
CSCs commonly possess de novo resistance to a wide 
range of anticancer drugs [1]. Furthermore we examined 
the chemosensitivity in these cells. Table 1 shows that 
resistance of BC cells to three first line anti-BC drugs was 
induced in both culture systems. These results suggest 
that the stemness and chemosensitivity in BC cells were 
not governed by the components in the culture medium. 
It has been reported that the hypoxic condition in the stem 
cell niche is essential for maintaining the stemness and 
chemoresistance [6]. We hypothesized that the hypoxic 
condition in the mammospheres may play the role in 
maintenance of stemness and chemoresistance. Fig. 1D 
and 1E demonstrate that in comparison with the adherent 
cells, high population of hypoxic cells were detected in 
both MSC and SUS cells by HypoxyProbe. Furthermore 
we cultured both cell lines in hypoxic condition (1% 
O2) for 5 days to determine the relationship between 
hypoxia and MSC characteristics. Fig. 1F to 1H show 
that the hypoxia-cultured monolayer cells express MSC 
markers and embryonic proteins. Similar to the MSC and 
SUS cells, the cells cultured in hypoxic condition are 
significantly resistant to chemotherapeutic agents (Table 
1). All of these data indicate that hypoxia may play a key 
role in determination of stemness and chemosentivity in 
BC cells. 
NFκB activation plays a pivotal role in 
maintaining CSC stemness and chemoresistance
High HIF2α nuclear protein was detected in the 
cells cultured in hypoxia, MSC and SUS conditions. 
IκBα degradation and NFκB p65 nuclear translocation 
were detected (Fig. 2A and 2B). NFκB p65 and AKT 
Phosphorylation and increased NFκB DNA binding 
activity were also detected in these cells (Fig. 2B and 2C). 
These results indicate that NFκB may be the pivotal factor 
in hypoxia-induced CSC characteristics. To examine the 
importance of NFκB in maintenance of stemness and 
chemosensitivity, both MCF7 and T47D cell lines were 
transfected with NFκB p65 subunit. High p65 protein 
levels and transcriptional activity of NFκB were detected 
in the transformed clones (Fig. 2D and 2E). Fig. 2F shows 
that the transformed clones possess significantly higher 
(p<0.01) population of CSCs (ALDH+, CD24low/CD44high). 
In comparison with the mock-transfected cells, the p65 
transfected cell lines are highly resistant to three first 
line anti-BC drugs [doxorubicin (Dox), PTX and dFdC] 
(Table 1). These data suggest that NFκB plays a key role 
in hypoxia-induced CSCs and chemoresistance.
Lipo-DS targets CSCs in vitro 
CuCl2 (10µM) was used in all the experiments 
because Cu is essential for DS induced cytotoxicity [21, 
27, 35]. Lipo-DS/Cu was highly cytotoxic to MSCs (Fig. 
3A) although these cells are resistant to conventional anti-
BC drugs (Table 1). Lipo-DS/Cu induced and inhibited 
expression of Bax and Bcl2 proteins respectively (Fig. 
3B). The sphere-forming ability was also completely 
abolished after 4 hours exposure to Lipo-DS/Cu but 
not Lipo-DS and Cu alone (Fig. 3C). The ALDH+ and 
CD24low/CD44high CSC population in the mammospheres 
was eliminated by Lipo-DS/Cu but not Lipo-DS, Cu and 
anti-BC drugs (Fig. 3D and 3E). Four ALDH isoenzymes 
(1A1, 1A3, 2 and 3A1) are most possible to be involved in 
the ALDH activity in CSCs [32, 36-38]. The mRNA and 
protein of these isoenzymes were examined to determine 
if Lipo-DS also inhibits ALDH at transcriptional and 
translational levels. Although most of the previous 
publications mentioned that ALDH1A1 is responsible for 
ALDH activity in CSCs, we could not detect its expression 
in both attached and sphere-cultured MCF7 and T47D 
Table 1: Cytotoxicity of conventional anticancer drugs in BC cell lines
MCF7 T47D
dFdC Dox PTX dFdC Dox PTX
ATT 28.7 (7.6) 17.1 (1.1) 6.3 (1.6) 76.3 (5.7) 64.2 (2.4) 7.7 (2.4)
MSC >1000 >2000 >1000 >1000 >2000 >1000
SUS >1000 >2000 >1000 >1000 >2000 >1000
Hypo >1000 >2000 >1000 >1000 >2000 >1000
Mock 14.8 (5.2) 63.2 (12.9) 2.8 (0.4) 2.5 (2.0) 169.8 (42.5) 6.2 (1.8)
C2 >1000 424.3** (65.5) >1000 N/A N/A N/A
P1 >1000 159.8** (36.8) >1000 N/A N/A N/A
C1 N/A N/A N/A >1000 498** (130) >1000
C3 N/A N/A N/A >1000 >1000 >1000
The figure represents IC50 value from three MTT experiments [mean (SD)]. The cells were exposed to drugs for 72 
hours. ATT: attached cells; MSC: mammosphere cells; SUS: suspension culture in normal medium; Hypo: hypoxic 
culture (O2 < 1%). Mock: Empty vector transfected cells; C2, P1, C1, C3: NFκB p65 transfected clones. ** p<0.01 
(n=3) compared with Mock cells. 
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Figure 1: Hypoxia induces expression of stem cell markers in BC cell lines. A. The morphology of spheres cultured in serum-
free (MSC) and serum-containing (SUS) medium (40× magnification). B. Flow cytometric analysis of ALDH activity and expression of 
CD24, CD44, Oct4, Sox2 and Nanog proteins in monolayer- and suspension-cultured cells. In comparison with the attached cells, all of 
these markers are expressed significantly higher in MSC and SUS (p<0.01). C. Specificity of ALDEFUOR in detection of ALDH activity in 
BC cell lines. DEAB: specific inhibitor of ALDH. D. Flow cytometric detection of hypoxic cells stained with Hypoxyprobe. Significantly 
higher population of hypoxic cells was detected in MSC and SUS cells (p<0.01). E. Confocal microscopy images of the hypoxic cells 
detected by Hypoxyprobe in serum-free (MSC) and serum-containing (SUS) medium cultured BC cells (×400 magnification). F and G. 
Hypoxyprobe stained hypoxic population in hypoxia-cultured BC cells was detected by flow cytometry (F) and immunocytochemistry (G) 
respectively. H. Flow cytometric comparison of ALDH activity and expression levels of CD24, CD44, Oct4, Sox2 and Nanog proteins 
in normoxia- and hypoxia-cultured cells. In comparison with the normoxic cells, stem cell markers were detected in significantly higher 
population of the hypoxic cells (p<0.01). ATT: monolayer culture; MSC: serum-free stem cell culture; SUS: serum-containing medium 
culture; Norm: normoxia; Hypo: hypoxia. The numbers in the frame represent Mean (SD) from three experiments.
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Figure 2: NFκB is responsible for maintaining CSC characters in suspension- and hypoxia-cultured cells. A. High levels 
of NFκB p65 and HIF2α protein were detected in the nuclear protein extracted from suspension- and hypoxia-cultured cells. Nuc: nucleolin 
used as a loading standard. B. Phosphorylated AKT, NFκB p65_Ser276 and degradation of IκBα were detected in suspension- and hypoxia-
cultured cells by western blot. α-Tub: α-tubulin used as a loading control. C. High NFκB DNA binding activity was detected by EMSA. Mut 
and WT: mutant and wild type probe competition. D and E. High NFκB p65 protein (D) and transcriptional activity (E) were detected in 
p65 transfected clones (C1, C3, P1 and C2) by western blot and luciferase reporter gene assay respectively. Mock: empty vector transfected 
cells. F. High ALDH+ and CD24low/CD44high population was detected in NFκB p65 transfected clones.
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Figure 3: Cytotoxic effect of Lipo-DS/Cu on BCSCs. A. Comparable cytotoxicity of Lipo-DS/Cu in monolayer-cultured cells and 
BCSCs was detected by MTT assay. The cells were exposed to Lipo-DS/Cu for 72 hours. B. Lipo-DS/Cu induced Bax and cleaved PARP 
and reduced Bcl2 expression were detected by western blot. The cells were treated in Lipo-DS (1µM)/CuCl2(10µM) for 4 hours and in drug-
free free stem cell culture medium for 24 hours. C. Lipo-DS/Cu abolished sphere-forming ability in BC cell lines. The cells were cultured 
in Lipo-DS (1µM), CuCl2 (10µM) or Lipo-DS/CuCl2 for 4 hours and in drug-free free stem cell culture medium for 7 days. D. The effect of 
different treatments on CD24low/CD44high population. E. The effect of different treatments on ALDH activity in BCSCs. For experiments D 
and E, 7-day-cultured sphere cells were trypsinized and exposed to different agents for 4 hours, then released for 24 hours. (** in D and E: 
In comparison with other groups, p<0.01) F. Expression of ALDH mRNAs in attached and spheroid cells. G. Lipo-DS/Cu did not influence 
the expression of ALDH proteins in CSCs. The whole proteins were extracted from the BCSCs exposed to different agents for 4 hours and 
released in drug-free medium for 24 hours.
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cells. ALDH2, a mitochondria-located isoenzyme, was 
expressed at background levels and not induced in CSCs. 
In contrast, the mRNA and protein of ALDH1A3 and 3A1 
were expressed at very low levels in the attached cells 
and markedly induced by MSC culture (Fig. 3F and 3G). 
Therefore ALDH1A3 and 3A1 may contribute to the high 
ALDH activity in the CSCs derived from MCF7 and T47D 
cell lines. Although Lipo-DS/Cu inhibited ALDH activity 
but it had no effect on the mRNA and protein expression 
of these 4 isoenzymes. 
Lipo-DS/Cu simultaneously triggers ROS-MAPK 
activation and inhibits NFκB pathway in MSCs
We previously reported that DS/Cu activates ROS-
MAPK and inhibits NFκB pathways in attached cells 
Figure 4: Lipo-DS/Cu induces ROS-MAPK and inhibits NFκB pathways and specifically targets BC cells. A. Top: Flow 
cytometric detection of Lipo-DS/Cu-induced ROS activity in BC cells. Dot-line: control, Solid-line: Lipo-DS/Cu. Bottom: Lipo-DS/Cu-
induced ROS activity was reversed by NAC. +VE: positive control (Pyocyanin 200µM). B. The Lipo-DS/Cu-induced cytotoxicity was 
reversed by NAC. C. Lipo-DS/Cu specifically induced ROS activity in BC cell lines. Relative ROS activity = (Treated/untreated) × 100%. 
D. Lipo-DS/Cu demonstrated specific cytotoxicity in BC cell lines. Relative viability = (Treated/untreated) × 100%. E. Clonogenic assay 
shows that Lipo-DS/Cu abolished colony-forming ability in BC cell lines but no effect on normal cell lines. The cells were exposed to 
drugs for 1 hour and released in drug free medium for 72 hours (MTT) and 10 days (clonogenic assay). F. The effect of different treatments 
on JNK, p38 and ERK pathways. G. Lipo-DS/Cu blocked NFκB p65 nuclear translocation. H. Lipo-DS/Cu induced IκBα expression and 
inhibited phosphorylation of AKT and NFκB p65. For F – H, 6-day-cultured spheres were trypsinized and exposed to different treatments 
(Lipo-DS 1µM, Cu 10µM, Lipo-DS/Cu) for 4 hours and release in drug-free medium for 24 hours.
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Figure 5: Lipo-DS inhibited growth of BC xenografts. MDA-MB-231 cells (1×106) were subcutaneously injected at one rear flank 
of the mice. When the tumor volume reached ~200mm3, the tumor bearing mice were randomly subdivided into 5 groups (8 mice/group) 
e.g. control; DS 75mg/kg p.o + CuGlu 8mg/kg p.o; CuGlu 8mg/kg p.o; Lipo-DS 75mg/kg i.v; Lipo-DS 75mg/kg i.v + CuGlu 8mg/kg p.o. 
The drugs were administered 3 times/week for successive 3 weeks. A. Growth curves of tumor size. Arrows represent drug administration. 
B. The effect of different treatments on tumor weight after 28 days observation. C. The effect of different treatment on Ki67 and TUNEL 
expression (×400 magnification). D. The effect of different treatments on BAX and Bcl-2 expression. E. Histo-pathological images of vital 
organs (H&E staining, 400 magnification).
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[21]. In this study, we examined the effect of Lipo-DS/
Cu on MSCs. Lipo-DS/Cu induced ROS activity in 
MSCs was reversed by NAC, a ROS inhibitor. NAC also 
reversed Lipo-DS/Cu induced cytotoxicity (Fig. 4A and 
B). In comparison with normal cell lines, Lipo-DS/Cu 
selectively induced higher ROS activity and cytotoxicity 
in cancer cells (Fig. 4C and 4D). After exposure to 
Lipo-DS/Cu for one hour, the clonogenicity in cancer 
cell lines was completely abolished but no significant 
effect was observed in Lipo-DS/Cu treated normal cells 
(MCF10A and HeCV)(Fig. 4E). After exposure to Lipo-
DS/Cu for 4 hours, the major MAPK pathway elements, 
e.g. phosphorylated JNK, phosphorylated C-JUN and 
phosphorylated p38 but not ERK, were significantly 
induced (Fig. 4F). In contrast to the MAPK pathway, Lipo-
DS/Cu inhibited IκBα degradation and blocked NFκB p65 
nuclear translocation in both MCF7 and T47D CSCs. The 
phosphorylation of NFκB p65 and AKT in the MSCs was 
also inhibited by Lipo-DS/Cu (Fig. 4G and 4H).
Disulfiram inhibits BC xenografts in vivo 
Furthermore, the anticancer efficacy of Lipo-
DS was examined in vivo. The drug was administered 
3 times/week for successive 3 weeks. To determine the 
necessity of copper supplement in vivo, the Lipo-DS i.v 
with/without copper supplement and copper alone were 
compared. The oral administration of DS/copper gluconate 
(CuGlu) was compared with i.v administration of Lipo-
DS plus oral administration of CuGlu. In comparison with 
the control group, both Lipo-DS/CuGlu and Lipo-DS 
significantly inhibited tumor growth but Lipo-DS/CuGlu 
demonstrated highest anticancer efficacy (Fig. 5A and 
5B). Oral administration of DS/CuGlu also showed tumor 
inhibiting effect although it is not statistically significant. 
Copper alone had no effect on tumor growth. Lipo-DS/
CuGlu, Lipo-DS and DS/CuGlu induced BAX, inhibited 
Bcl-2 and induced TUNEL staining (Fig. 5C and 5D). In 
comparison with the control group, the ALDH expression 
in tumor tissues was inhibited when the animal were 
treated with Lipo-DS/CuGlu and Lipo-DS (Fig. 5C). It 
seems that Lipo-DS/CuGlu had no effect on proliferation 
because the expression of Ki67 was not affected by the 
treatments. Administration of CuGlu with or without DS 
or Lipo-DS induced moderate dilation of blood vessels in 
the examined organs. No cytotoxic effect was observed 
in lung and kidney but some necrotic cells were observed 
in the liver of Lipo-DS/CuGlu treated animals (Fig. 5E).
DISCUSSION
Since Al-Hajj identified CSCs in BC [39], the 
existence of CSCs has been reported in several other 
cancer types and in developed cancer cell lines [40]. 
The CSC culture system is adapted from the normal 
stem cell culture system. The serum-free and growth 
factors-supplemented spheroid culture has been widely 
used as a gold method in vitro to prevent differentiation, 
purge the differentiated progenies and enrich stem cell 
population [41]. In contrast to the relatively nonreversible 
differentiation in normal stem cells, the monolayer-
cultured non-CSCs and sphere-cultured CSCs are 
completely reversible [6, 41]. In comparison with the 
stem cell culture system, the serum-rich suspended 
culture system is less costly and has better physiological 
relevance. In this study, we compared the BC cells cultured 
in traditional serum-free stem cell medium and serum-rich 
(10% FCS) medium to determine the necessity of the stem 
cell medium in maintaining the CSC status. After 6 days 
culture, the BC cells in both systems formed spheres and 
clusters (Fig. 1A). It is widely accepted that if it is not a 
single cell inoculation, the aggregation of the suspended 
cells is inevitable, no matter how low the cell density ([41] 
and our unpublished data). Therefore, these spheres and 
clusters represent both cell proliferation and aggregation. 
The expression of stem cell and embryonic markers 
was significantly induced in the cells cultured in both 
systems. This result indicates that the stemness was not 
determined by the components in the culture medium. If 
so, there must be some common feature(s) in the culturing 
systems which introduce and maintain stemness. Hypoxia 
is a determinant of stemness in stem cell niche [6]. We 
hypothesized that due to the penetrating distance hypoxia 
may be cumulated within the spheres. The cells located in 
the center of the spheres will show CSCs’ characteristics. 
Compared with the monolayer-cultured cells, a high 
population of hypoxic cells was detected in the sphere-
cultured cells (Fig. 1D and E). More hypoxic cells were 
detected in serum-containing spheres. This may be due to 
that these spheres are significantly bigger and tighter than 
those in serum-free culture (Fig. 1A). A high population of 
CSCs was also detected in hypoxia-cultured (<1% O2) BC 
cells. The BC cells cultured in these three conditions are 
highly resistant to dFdC, Dox and PTX. Chemoresistance 
is another common feature of CSCs. These results indicate 
that the stem cell characters in the sphere-cultured cells 
may be introduced by hypoxia. The serum-free and growth 
factors-supplemented medium is not essential for the in 
vitro CSC culture.
Although hypoxia can induce stem cell characters, 
the detailed molecular mechanisms and pathways 
linking hypoxia and CSCs are still largely unknown. 
It is generally believed that hypoxia-activated HIF 
pathways are important for cellular response to hypoxia 
[6]. However, many other transcription factors, e.g. 
NFκB, are also crucial for hypoxia-induced phenotypes. 
Activation of NFκB pathway enables the survival of the 
inflammatory cells in inflammation-induced hypoxia [6]. 
Recent studies indicate that NFκB also plays a pivotal 
role in CSCs and chemoresistance [42-44]. In our study, 
nuclear translocation of HIF2α and NFκB p65 protein 
Oncotarget7480www.impactjournals.com/oncotarget
was detected in sphere- and hypoxia-cultured cells. 
These cells also demonstrated IκBα degradation and p65 
phosphorylation. The activation of AKT, the transcription 
factor upstream of NFκB, was also observed. High NFκB 
DNA binding activity was induced in all three conditions. 
Therefore NFκB pathway is activated in all of the three 
culture systems (MSC, SUS and hypoxia). In order to 
examine the importance of NFκB in determination of 
CSC traits, we transfected BC cells with NFκB p65. The 
transfected clones expressed high levels of BCSC markers 
(Fig. 2F) and were highly resistant to dFdC, Dox and PTX 
(Table 1). Therefore NFκB definitely conferred CSC traits 
upon BC cells.
DS is an NFκB inhibitor which targets CSCs 
and reverses chemoresistance [21, 25, 27, 35, 45]. The 
application of DS in cancer therapeutics is limited by its 
very short half-life in the bloodstream [46]. To overcome 
this hindrance, we recently developed a Lipo-DS to extend 
the half-life of DS in the bloodstream [47]. In line with 
our previous reports [21, 27], the cytotoxicity of Lipo-DS 
is Cu dependent. After very short exposure (4 hours) to 
Lipo-DS/Cu, the expression of BCSC markers (ALDH+, 
CD24low/CD44high) in the sphere cells was inhibited and the 
sphere-forming ability in the BC cell lines was completely 
abolished. The BCSC markers were not affected by 
conventional anticancer drug, Lipo-DS or Cu. Although it 
was reported that ALDEFLOUR detects enzyme activity 
of ALDH1A1 [32], we could not detect ALDH1A1 
mRNA and protein expression in both cell lines. ALDH2, 
a mitochondrial isoenzyme, was detected at very low basal 
levels but not induced by spheroid and hypoxic culture. 
Marcato et al. [36] reported that ALDH1A3 is responsible 
for the high ALDH activity in BC. Our study indicates 
that both ALDH1A3 and 3A1 may be responsible for the 
high ALDH activity in BCSCs because high and inducible 
expression of ALDH1A3 and 3A1 mRNA and proteins 
was detected in sphere-cultured cells. Lipo-DS/Cu had no 
effect on ALDH isoenzymes (1A1, 1A3, 2 and 3A1) at 
mRNA and protein levels. 
Selectivity is one of the key issues for anticancer 
drug development. The cytotoxicity of Lipo-DS/Cu is ROS 
dependent. ROS induces apoptosis by damaging DNA, 
RNA and protein. Cancer cells possess and also tolerate 
significantly higher levels of ROS due to the balance of 
anti-apoptotic mechanisms e.g. NFκB [48]. Lipo-DS/Cu 
selectively induced ROS activity and showed significantly 
higher cytotoxicity in BC than normal cell lines. Similar 
phenomenon was also obtained by clonogenic assay (Fig. 
4E). ROS induced-apoptosis is highly MAPK pathway-
dependent. Lipo-DS/Cu persistently activated JNK, C-Jun 
and p38 MAPK pathways but had no effect on ERK 
pathway which is responsible for cell growth, proliferation 
and survival [49]. ROS also trigger the expression of 
anti-apoptotic proteins which in turn neutralize the pro-
apoptotic effects of ROS [48]. NFκB is one of the most 
important ROS-induced anti-apoptotic factors [48]. NFκB 
inhibits JNK and p38 activation and suppresses ROS 
accumulation in cancer cells [48, 50]. Cancer cell fate is 
highly dependent on the crosstalk between JNK/p38 and 
NFκB pathways. Simultaneous activation of ROS-JNK/
p38 and inhibition of NFκB pathway (Fig. 4F – 4H) may 
contribute to Lipo-DS/Cu induced cytotoxicity in the BC 
cell lines.
In this study, we first reported the anticancer 
effect of Lipo-DS in combination with copper in vivo. 
Lipo-DS/CuGlu demonstrated the strongest anticancer 
efficacy. Lipo-DS injection alone also showed anticancer 
activity although lower than that of Lipo-DS/CuGlu. This 
may be due to the intrinsic copper in plasma and tumor 
tissues [51]. Oral version of DS/Cu showed mild in vivo 
anticancer activity. The Lipo-DS, Lipo-DS/Cu and DS/Cu 
induced apoptosis was evidenced by TUNEL and western 
blotting results (Fig. 6C and 6D). Consistence with our in 
vitro data ([21] and unpublished data) Ki67 staining (Fig. 
6C) indicates that the anticancer effect of DS and Lipo-
DS is proliferation-independent. In line with the in vitro 
data, Lipo-DS inhibited the ALDH+ CSC population in the 
xenografts (Fig. 6C). To determine the in vivo selectivity 
DS, the histo-pathological changes of vital organs (liver, 
lung and kidney) were examined (Fig. 6E). CuGlu 
induced blood congestion in major organs. There was no 
significant toxicity observed in the vital organs except that 
some necrotic cells were observed in the liver of Lipo-
DS/Cu treated mice. Our unpublished data indicate that 
in combination with Cu, the in vivo anticancer effect of 
nano-encapsulated DS could be achieved at significantly 
lower dose with no toxicity in liver. Therefore the dose 
of Lipo-DS in Lipo-DS/CuGlu group still needs to be 
adjusted. After very short exposure (1 hour) in vitro, 
Lipo-DS showed high selectivity and strong irreversible 
cytotoxicity in cancer cells. This phenomenon gives us 
a further indication that development of long-circulating 
formulation of DS may translate this drug into clinical 
cancer therapeutics. 
MATERIALS AND METHODS
Cell lines and reagents
The breast cancer cell lines MCF7, MDA-MB-231, 
T47D and normal breast epithelial cell line MCF10A 
were purchased from ATCC (Middlesex, UK). HeCV, 
the normal human vascular endothelial cell line, [52] was 
kindly provided by Prof W Jiang (Cardiff University, UK). 
Gemcitabine (dFdC), doxorubicin (Dox), paclitaxel (PTX), 
copper(II) chloride (CuCl2), copper gluconate (CuGlu), 
N-acetyl-cysteine (NAC) and poly-2-hydroxyethyl 
methacrylate (poly-HEMA) were purchased from Sigma 
(Dorset, UK). Lipo-DS was provided by Prof X Tang 
(Shenyang Pharmaceutical University, China). The drug 
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loading content of Lipo-DS is 3mg/ml. The cumulative 
release of DS from liposome in 120h is more than 60%. 
The pharmacokinetic study of DSF in rat plasma after 
intravenous administration of a dose of 36 mg/kg has been 
investigated (t1/2 =0.1 h and t1/2d=0.3 h). The comparison of 
the biological activity between Lipo-DS and conventional 
DS has been published [53].
Cell culture and cytotoxicity analysis
All cell lines were cultured in DMEM (Lonza, 
Wokingham, UK) supplemented with 10% FCS, 
2mM L-glutamine, 50 units/ml penicillin, 50 μg/ml 
streptomycin. For in vitro cytotoxicity assay, the cells 
(5,000/well) were cultured in 96-well flat-bottomed 
microtiter plates overnight and exposed to anticancer 
drugs or Lipo-DS plus CuCl2 (10µM) for 72 h, then 
subjected to a standard MTT assay [54].
In vitro mammosphere and suspension culture 
and cytotoxicity assay 
To culture the BC spheres, cells were cultured in 
poly-HEMA coated ultra-low adherence flasks or plates 
to prevent cell adhesion. The spheres were cultured, at a 
density of 10,000 cells/ml, as MSCs or suspension cells 
(SUS) in stem cell culture medium [SCM, serum-free 
DMEM-F12 supplemented with B27 (Invitrogen, Paisley, 
UK), 20 ng/ml epidermal growth factor (EGF, Sigma), 
10 ng/ml basic fibroblasts growth factor (b-FGF, R & 
D System, Abingdon, UK), 10 µg/ml insulin (Sigma)] 
and full medium (DMEM supplemented with 10% FCS, 
2mM L-glutamine, 50 units/ml penicillin, 50 µg/ml 
streptomycin) respectively. After 6 days culture, the MSC 
and SUS cell clusters and spheres were photographed and 
subjected to further treatments. For in vitro cytotoxicity 
assay, the MSC or SUS cultured cells were trypsinised and 
seeded in 96-well plated at a density of 5,000 cells/well 
and exposed to drugs for 72 h before MTT assay. CuCl2 
(10 µM) supplemented culture medium was used in the 
MTT assay to determine the cytotoxicity of Lipo-DS in 
MSC and SUS.
Measurement of hypoxia in cell culture
The hypoxic status was determined using the 
HypoxyprobeTM-1 Plus Kit supplied by Hypoxyprobe 
Inc (Burlington, MA, USA) following the supplier’s 
instruction. For immunocytochemistry assay, the cells 
were cultured in 8-well chamber slides at normoxic (20% 
oxygen) or hypoxic [1% oxygen in Hypoxic Chamber 
(StemCell, Durham, NC, USA)] condition for 24 hours 
and labeled with Hypoxyprobe for 2 hours. The hypoxic 
cells were detected by confocal microscope after stained 
with FITC-conjugated anti-hypoxyprobe MAb. The CSCs 
and cells in suspending condition were cultured for 6 days. 
The MSCs and suspension-cultured cells were labelled 
with Hypoxyprobe for 24 hours and cytospined at 800 
rpm for 3 min to spread the spheres onto Polylysine-coated 
slides (VWR, Lutterworth, UK). For flow cytometric 
analysis, the cells were cultured in 25cm flasks at the 
above conditions. After immunocytochemistry staining 
the cells were subjected to flow cytometric analysis. The 
hypoxic population was detected using a FACSCalibur 
flow cytometer with 488-nm blue laser and standard FITC 
530/30 nm bandpass filter. To determine the effect of 
hypoxia on drug sensitivity, the cells were cultured in 1% 
oxygen condition at a cell density of 1×103 cells/well in 
96-well plate for 4 days and exposed to anticancer drugs 
for another 72 h before MTT assay. The parallel MTT 
assay was performed in normoxic condition.
Detection of ALDH positive population
The ALDH positive population was detected by 
ALDEFLUOR kit (StemCell Tech., Durham, NC, USA) 
following the supplier’s instruction. The cells (2.5 × 105) 
were analyzed after stained in ALDH substrate containing 
assay buffer for 30 min at 37°C. The negative control 
was treated with diethylaminobenzaldehyde (DEAB), a 
specific ALDH inhibitor.
Flow cytometric analysis of CD24 and CD44 
expression
The adherent or mammosphere cells were 
trypsinised and passed through a 25G needle. The 
cells (2.5 × 105) were incubated with CD24 and CD44 
antibodies (BD Pharmingen, Oxford, UK) for 20 min 
at 4°C. Unbound antibodies were washed off with 2% 
FCS HBSS (Sigma) and the cells (10,000 events) were 
examined no longer than 1 hour after staining on a BD 
Facscalibur.
Immunofluorescent flow cytometric analysis of 
embryonic stem cell markers
The expression of Nanog, Oct4 and Sox2 was 
determined by immunofluoresent flow cytometry. The 
sphere and hypoxia-cultured cells were collected by 
trypsinization. The cells fixed by acetone/methanol 
and permeabilized by 0.1% triton-X100. After blocked 
with 3% BSA for 1 hour the cells were stained with 
primary (1:50 dilution) and FITC-conjugated secondary 
antibodies respectively for 1 hour at RT. The positively 
stained population was detected using a FACSCalibur 
flow cytometer with 488-nm blue laser and standard FITC 
530/30 nm bandpass filter.
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Western blotting analysis
The protein expression levels were determined 
by staining with primary antibodies and relevant 
HRP conjugated secondary (1:5000, Armersham, 
Buckinghamshire, UK) antibodies. The primary 
antibodies (Santa Cruz, CA, USA: Bcl2, Bax, p65, IκBα, 
nucleolin, ALDH1A1, 1A3, 3A1, 2 and cleaved PARP; 
Novus Bio, Cambridge, UK: HIF2; Abcam, Cambridge, 
UK: phosphorylated p65_S276; Cell Signaling, Herts, 
UK: AKT, phosphorylated AKT, Sox2, Oct4, JNK, 
phosphorylated JNK, cJun, phosphorylated cJun, 
phosphorylated p38, ERK) were diluted at 1:1000 in 5% 
fat-free milk-TBST. Anti-α-tubulin (1:8000, Sigma) and 
nucleolin were used as a loading control. The signal was 
detected using an ECL Western blotting detection kit 
(GeneFlow, Staffordshire, UK).
Electrophoretic mobility-shift assays (EMSA)
Nuclear protein extraction was carried out as 
previously described [21]. A double-stranded NFκB 
DNA probe (5′-AGT TGA GGG GAC TTT CCC AGG 
C-3′) was end labeled with biotin. Detection of NFκB-
oligonucleotide complex was performed using a LightShift 
chemiluminescent EMSA kit (Pierce, Northumberland, 
UK). Briefly, nuclear protein (5 µg) was incubated with 20 
fmol of biotin-labeled oligonucleotide for 20 min at room 
temperature in binding buffer consisting of 10 mM Tris at 
pH 7.5, 50 mM KCl, 1 mM DTT, 2.5% glycerol, 5 mM 
MgCl2, 50 ng of poly(dIdC), and 0.05% Nonidet P-40. The 
specificity of the NFκB DNA binding was determined in 
competition reactions in which a 200-fold molar excess of 
unlabeled wild type or mutant NFkB probe (5′-AGT TGA 
TAT TAC TTT TAT AGG C-3′) was added to the binding 
reaction. Products of binding reactions were resolved 
by electrophoresis on a 6% polyacrylamide gel. NFκB-
oligonucleotide complex was electroblotted onto a nylon 
membrane (Amersham). After incubation in blocking 
buffer for 1 hour at room temperature, the membrane 
was incubated with streptavidin-HRP conjugate for 30 
min at room temperature. The membrane was incubated 
with chemiluminescent substrate for 5 min and exposed to 
radiographic film.
Luciferase reporter gene assay
The effect of different treatments on the 
transcriptional activity of NFκB was determined by 
luciferase reporter gene assays. Transfections were 
performed using Lipofectamine 2000 transfection reagent 
according to the manufacturer’s instructions (Invitrogen, 
Paisley, UK). Cells (1 × 104/well) were cultured in 96-well 
plates overnight. The luciferase reporter vectors (0.8µg/
well) [pNFκB-Tal-Luc (BD Biosciences) and pGL3-
Basic (Promega, Southampton, UK)] were co-transfected 
with 0.008 µg/well pSV40-Renilla (Promega) DNA, an 
internal control for normalization of the transcriptional 
activity of the reporter vectors. Twenty-four hours 
after transfection, the cells were lysed and luciferase 
activity was determined using Dual Luciferase Assay kit 
(Promega) according to the manufacturer’s instructions. 
The luciferase activity in each well was normalized to 
pSV40-Renilla using Ln = L/R (Ln: normalized luciferase 
activity; L: luciferase activity reading; R: Renilla activity 
reading). The transcriptional specificity was monitored 
by the transcriptional activity of the pGL3-Basic. All 
transfections were performed in triplicate with at least 
duplicate independent experiments.
Measurement of ROS activity
The intracellular ROS levels were determined using 
a Total ROS Detection Kit (Enzo, Exeter, UK) following 
the supplier’s instruction. Briefly, the cancer cells (2×105 
cells/well) were cultured in 6-well plate until 70% 
confluence. The cells were exposed to Lipo-DS (1 µM) in 
combination with Cu (10 µM). Cells exposed to NAC (2 
mM) were used as a negative control. After drug exposure, 
the drug containing medium was discarded and the cells 
were collected by trypsinization. The cell pellets were 
resuspended and incubated in 500 µl of ROS Detection 
Solution at 37˚C for 30 min in the dark. The ROS positive 
population was detected using a FACSCalibur flow 
cytometer with 488-nm blue laser and standard FITC 
530/30 nm bandpass filter.
Clonogenic Assay
Cells (5×104/well) were cultured in 6-well plates 
overnight and then exposed to 1 µM of DS in combination 
with 10µM CuCl2 for 1 h. The cells were collected and 
cultured in 6-well plates containing drug-free medium 
at a cell density of 2.5×103/well. Clonogenic cells were 
determined as those able to form a colony consisting of at 
least 50 cells after 10 days culture.
Total RNA isolation and RT-PCR
Total RNA was isolated using TRIzol reagent 
(Invitrogen, Paisley, UK) according to the manufacturer’s 
protocols. The mRNA expression levels of ALDH 1A1 
(NM_000689), 1A3 (NM_000693), 2 (NM_000690) 
and 3A1 (NM_000691) genes were determined using 
the Access RT-PCR System (Promega, Southampton, 
UK) following the instruction of the supplier. The human 
housekeeping gene GAPDH (XR018317) was used as 
the RNA loading control. The sequences of the primers 
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and the sizes of the amplified fragments are as follows. 
1A1 (154 bp): F: 5’-TGTTAGCTGATGCCGACTTG-3’, 
R: 5’-TTCTTAGCCCGCTCAACACT-3’; 1A3 (150 
bp): F: 5’-TCTCGACAAAGCCCTGAAGT-3’, R: 
5’-TATTCGGCCAAAGCGTATTC-3’; ALDH2 (193 
bp) F: 5’- AACCAGCAGCCCGAGGTCTT-3’, R: 
5’- AAGGTGAGCCCAGCTGGAAG-3’; 3A1 (229 
bp) F: 5’-TGTTCTCCAGCAACGACAAG-3’, R: 
5’-CTGACCTTCAGGCCTTCATC-3’; GAPDH 
(226bp) F: 5´-GAAGGTGAAGGTCGGAGTC-3´, R: 
5´- GAAGATGGTGATGGGATTTC-3´. The RT-PCR 
conditions were as follows: One cycle at 48°C for 45 min; 
1 cycle at 94°C for 2 min; 35 cycles at 94°C for 30 sec, 
60°C for 30 sec, 72°C for 1 min; 1 cycle at 72°C for 5 min.
Human breast cancer xenograft experiments
Five-week-old female BALB/c Nu/Nu athymic nude 
mice (Biotechology & Cell Biology Shanghai, China) 
were housed under pathogen-free conditions according 
to the animal care guidelines of Fourth Military Medical 
University (FMMU), China. The animal experiments 
were reviewed and approved by the Ethical Committee 
of FMMU. The animal study regimen is detailed in Fig. 
6. The tumor volume was calculated by the following 
formula: V =(L×W2)×0.5, where L is the length and W is 
the width of the tumor. The xenograft size was observed 
twice per week for 4 weeks. After 4 weeks or when the 
xenograft reached 1500mm3, the animals were sacrificed. 
The tumors were removed, photographed and subjected to 
further analysis.
Immunohistochemistry and H&E staining
The paraffin embedded tumor and normal tissue 
sections were stained using Ki67 (1:200, Cell signaling) 
and ALDH1 (1:100, Abcam) antibodies then stained 
with biotinylated anti-mouse immunoglobulin G (H + 
L) secondary antibody followed by incubation in ABC 
reagent (DAKO Labs, Cambridgeshire, UK). For H&E 
staining, the slides were deparaffinized, rehydrated and 
stained with hematoxylin and eosin for 1 minute. The slide 
was mounted with 3,3’-diaminobenzidine and visualized 
under a light microscope.
Terminal deoxyribonucleotidyl transferase–
mediated dUTP nick end labeling (TUNEL) assay
Tumor tissues were paraffin embedded and stained 
according to the instruction of the manufacturer (Roche, 
West Sussex, UK). Briefly, the slides were incubated with 
TdT Enzyme, Stop/Wash Buffer, antidigoxigenenin, and 
then stained with peroxidase substrate and incubated 
in ABC reagent. Finally, the slide was mounted with 
3,3’-diaminobenzidine and visualized under a light 
microscope.
Statistical Analysis
SPSS 13.0 Student’s t test and one way analysis 
of variance (ANOVA) followed by Tukey’s Multiple 
Comparison Test were used to calculate the differences. 
Data were expressed as mean±SD. P≤0.05 was considered 
as significantly change.
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